Overview

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Status:
Recruiting

Trial end date:
2024-08-01

Target enrollment:

Participant gender:

Summary

This is a prospective multicenter clinical study to determine the efficacy and safety of hypofractionated radiotherapy combined with PD-1 inhibitor sequential GM-CSF and IL-2 for advanced multiple metastatic solid tumors

Phase:

Phase 2

Details

Lead Sponsor:

Second Affiliated Hospital of Soochow University

Treatments:

Immune Checkpoint Inhibitors